CO2022012196A2 - Composiciones y métodos para la edición de genes de calicreína (klkb1) - Google Patents

Composiciones y métodos para la edición de genes de calicreína (klkb1)

Info

Publication number
CO2022012196A2
CO2022012196A2 CONC2022/0012196A CO2022012196A CO2022012196A2 CO 2022012196 A2 CO2022012196 A2 CO 2022012196A2 CO 2022012196 A CO2022012196 A CO 2022012196A CO 2022012196 A2 CO2022012196 A2 CO 2022012196A2
Authority
CO
Colombia
Prior art keywords
compositions
methods
klkb1
kallikrein
gene editing
Prior art date
Application number
CONC2022/0012196A
Other languages
English (en)
Inventor
Shobu Odate
Jessica Lynn Seitzer
Original Assignee
Intellia Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intellia Therapeutics Inc filed Critical Intellia Therapeutics Inc
Publication of CO2022012196A2 publication Critical patent/CO2022012196A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/712—Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0066—Manipulation of the nucleic acid to modify its expression pattern, e.g. enhance its duration of expression, achieved by the presence of particular introns in the delivered nucleic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102—Mutagenizing nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/322—2'-R Modification

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Fodder In General (AREA)
  • Medicinal Preparation (AREA)

Abstract

Se proporcionan composiciones y métodos para editar, por ejemplo, introducir roturas bicatenarias, dentro del gen KLKB1. Se proporcionan composiciones y métodos para tratar sujetos que tienen angioedema hereditario (HAE).
CONC2022/0012196A 2020-02-07 2022-08-26 Composiciones y métodos para la edición de genes de calicreína (klkb1) CO2022012196A2 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202062971906P 2020-02-07 2020-02-07
US202062981965P 2020-02-26 2020-02-26
US202063019076P 2020-05-01 2020-05-01
PCT/US2021/016730 WO2021158858A1 (en) 2020-02-07 2021-02-05 Compositions and methods for kallikrein ( klkb1) gene editing

Publications (1)

Publication Number Publication Date
CO2022012196A2 true CO2022012196A2 (es) 2022-09-09

Family

ID=74873798

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2022/0012196A CO2022012196A2 (es) 2020-02-07 2022-08-26 Composiciones y métodos para la edición de genes de calicreína (klkb1)

Country Status (15)

Country Link
US (4) US20230295587A1 (es)
EP (1) EP4100528A1 (es)
JP (1) JP2023512758A (es)
KR (1) KR20220139352A (es)
CN (1) CN115362256A (es)
AU (1) AU2021216451A1 (es)
BR (1) BR112022015380A2 (es)
CA (1) CA3169813A1 (es)
CL (1) CL2022002095A1 (es)
CO (1) CO2022012196A2 (es)
IL (1) IL295280A (es)
MX (1) MX2022009658A (es)
PH (1) PH12022552009A1 (es)
SA (1) SA522440054B1 (es)
WO (1) WO2021158858A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12042509B2 (en) 2021-10-01 2024-07-23 Adarx Pharmaceuticals, Inc. Prekallikrein-modulating compositions and methods of use thereof
WO2023086953A1 (en) * 2021-11-11 2023-05-19 Beam Therapeutics Inc. Compositions and methods for the treatment of hereditary angioedema (hae)
TW202346586A (zh) * 2022-01-28 2023-12-01 大陸商上海舶望製藥有限公司 用於抑制前激肽釋放酶（pkk）蛋白表達的組合物和方法
WO2024011206A1 (en) * 2022-07-08 2024-01-11 Intellia Therapeutics, Inc. Methods for in vivo editing of klkb1
WO2024012435A1 (en) * 2022-07-11 2024-01-18 CorrectSequence Therapeutics Co., Ltd Gene editing systems and methods for treating hereditary angioedema
WO2025096980A1 (en) * 2023-11-02 2025-05-08 Poseida Therapeutics, Inc. Compositions targeting klkb1 and methods of use thereof
WO2025128871A2 (en) 2023-12-13 2025-06-19 Renagade Therapeutics Management Inc. Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents
CN118303422B (zh) * 2024-04-17 2024-11-12 华南师范大学 Ppk基因在控制德国小蠊繁殖行为中的应用
WO2026008078A1 (en) * 2024-07-05 2026-01-08 Shanghai Vitalgen Biopharma Co., Ltd. Methods for kallikrein (klkb1) gene editing

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5585481A (en) 1987-09-21 1996-12-17 Gen-Probe Incorporated Linking reagents for nucleotide probes
US5378825A (en) 1990-07-27 1995-01-03 Isis Pharmaceuticals, Inc. Backbone modified oligonucleotide analogs
JP3131222B2 (ja) 1991-12-24 2001-01-31 アイシス・ファーマシューティカルス・インコーポレーテッド ギャップを有する２′修飾オリゴヌクレオチド
JPH10500310A (ja) 1994-05-19 1998-01-13 ダコ アクティーゼルスカブ 淋菌及びトラコーマ クラミジアの検出のためのｐｎａ プローブ
EP3320922A1 (en) * 2011-06-10 2018-05-16 Ionis Pharmaceuticals, Inc. Methods for modulating kallikrein (klkb1) expression
WO2014093655A2 (en) 2012-12-12 2014-06-19 The Broad Institute, Inc. Engineering and optimization of systems, methods and compositions for sequence manipulation with functional domains
US20140310830A1 (en) 2012-12-12 2014-10-16 Feng Zhang CRISPR-Cas Nickase Systems, Methods And Compositions For Sequence Manipulation in Eukaryotes
DK2931891T3 (da) 2012-12-17 2019-08-19 Harvard College Rna-styret modificering af menneskelige genomer
KR102365486B1 (ko) * 2013-08-28 2022-02-18 아이오니스 파마수티컬즈, 인코포레이티드 프리칼리크레인 (pkk) 발현의 조절
US20150165054A1 (en) 2013-12-12 2015-06-18 President And Fellows Of Harvard College Methods for correcting caspase-9 point mutations
EP3083556B1 (en) * 2013-12-19 2019-12-25 Novartis AG Lipids and lipid compositions for the delivery of active agents
HUE052709T2 (hu) * 2014-05-01 2021-05-28 Ionis Pharmaceuticals Inc Módosított antiszensz oligonukleotidok konjugátumai és azok alkalmazása PKK expressziójának módosítására
WO2015200555A2 (en) 2014-06-25 2015-12-30 Caribou Biosciences, Inc. Rna modification to engineer cas9 activity
CN106794141B (zh) 2014-07-16 2021-05-28 诺华股份有限公司 将核酸包封在脂质纳米粒主体中的方法
KR20230156800A (ko) 2015-03-03 2023-11-14 더 제너럴 하스피탈 코포레이션 변경된 PAM 특이성을 갖는 조작된 CRISPR-Cas9 뉴클레아제
JP6695902B2 (ja) * 2015-05-06 2020-05-20 アルナイラム ファーマシューティカルズ， インコーポレイテッドＡｌｎｙｌａｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 第ＸＩＩ因子（ハーゲマン因子）（Ｆ１２）、カリクレインＢ、血漿（フレッチャー因子）１（ＫＬＫＢ１）、及びキニノーゲン１（ＫＮＧ１）ｉＲＮＡ組成物及びその使用方法
WO2017136794A1 (en) 2016-02-03 2017-08-10 Massachusetts Institute Of Technology Structure-guided chemical modification of guide rna and its applications
US20180112234A9 (en) * 2016-03-14 2018-04-26 Intellia Therapeutics, Inc. Methods and compositions for gene editing
LT3436077T (lt) 2016-03-30 2025-06-25 Intellia Therapeutics, Inc. Lipidų nanodalelių vaisto formos, skirtos crispr/cas komponentams
CA3035534A1 (en) * 2016-09-07 2018-03-15 Sangamo Therapeutics, Inc. Modulation of liver genes
SG10202106058WA (en) 2016-12-08 2021-07-29 Intellia Therapeutics Inc Modified guide rnas
EP3649243A1 (en) * 2017-07-07 2020-05-13 Alnylam Pharmaceuticals, Inc. Methods for treating or preventing contact-activation pathway-associated diseases using irna compositions targeting factor xii (hageman factor) (f12)
WO2019067910A1 (en) 2017-09-29 2019-04-04 Intellia Therapeutics, Inc. POLYNUCLEOTIDES, COMPOSITIONS AND METHODS FOR GENOMIC EDITION
US20230140670A1 (en) 2017-09-29 2023-05-04 Intellia Therapeutics, Inc. Formulations
AU2019282824C1 (en) 2018-06-08 2026-04-23 Intellia Therapeutics, Inc. Modified guide RNAS for gene editing
US12521451B2 (en) * 2019-11-08 2026-01-13 Regeneron Pharmaceuticals, Inc. CRISPR and AAV strategies for x-linked juvenile retinoschisis therapy

Also Published As

Publication number Publication date
US20260022358A1 (en) 2026-01-22
BR112022015380A2 (pt) 2022-09-27
PH12022552009A1 (en) 2024-02-05
CA3169813A1 (en) 2021-08-12
WO2021158858A1 (en) 2021-08-12
KR20220139352A (ko) 2022-10-14
MX2022009658A (es) 2022-10-27
JP2023512758A (ja) 2023-03-29
TW202146030A (zh) 2021-12-16
SA522440054B1 (ar) 2025-04-21
CL2022002095A1 (es) 2023-03-10
IL295280A (en) 2022-10-01
US12480109B2 (en) 2025-11-25
CN115362256A (zh) 2022-11-18
US20250197828A1 (en) 2025-06-19
US20240018496A1 (en) 2024-01-18
EP4100528A1 (en) 2022-12-14
AU2021216451A1 (en) 2022-09-29
US20230295587A1 (en) 2023-09-21

Similar Documents

Publication Publication Date Title
CO2022012196A2 (es) Composiciones y métodos para la edición de genes de calicreína (klkb1)
CO2021005231A2 (es) Composiciones y métodos para la edición génica de lactato deshidrogenasa (ldha)
MX2020003608A (es) Composiciones y métodos para la edición del gen ttr y el tratamiento de la amiloidosis attr.
MX2021011565A (es) Composiciones y métodos que comprenden un arn guía de ttr y un polinucleótido que codifica un agente de fijacion a adn guiado por arn.
CO2021002691A2 (es) Composiciones y métodos para editar el gen hidroxiácido oxidasa 1 (hao1) para tratar la hiperoxaluria primaria tipo 1 (ph1)
CO2019007776A2 (es) Composiciones y métodos para tratar la deficiencia de alfa-1 antitripsina
MX2025007610A (es) Composiciones de arni de 17beta-hidroxiesteroide deshidrogenasa tipo 13 (hsd17b13) y metodos de uso de las mismas
CO2022006092A2 (es) Métodos y composiciones para el tratamiento de un trastorno asociado con angiotensinógeno (agt)
MX2015012176A (es) Metodos de usar zscan4 para rejuvenecer celulas humanas.
EA201991369A1 (ru) Модифицированные направляющие рнк
CL2024001429A1 (es) Composiciones y métodos para inhibir la expresión de la proteína angiotensinógeno (agt)
CO2021014562A2 (es) Composiciones y métodos para la edición del gen ttr y el tratamiento de la amiloidosis attr que comprenden un corticosteroide o el uso de este
CL2021001552A1 (es) Moléculas inhibidoras de ácido nucleico de doble hebra que contienen un triloop
EP4484443A3 (en) Materials and methods for treatment of friedreich ataxia and other related disorders
CL2022001260A1 (es) Tratamiento del angioedema hereditario con vectores de terapia de genes específicos del hígado
MX2020012652A (es) Oligonucleotido bicatenario especifico del gen de anfirregulina y composicion para prevenir y tratar enfermedades relacionadas con la fibrosis y enfermedades respiratorias, que comprende el mismo.
BR112022012867A2 (pt) Tratamento de câncer com inibidores de cdk12/13
CO2022006367A2 (es) Tratamiento génico para la enfermedad de alzheimer
MX2022005358A (es) Composiciones de copolímero de bloque sensibles al ph, micelas, y métodos de uso.
MX2020006005A (es) Copolimeros bloque anfifilicos, micelas y metodos para tratar o prevenir insuficiencia cardiaca.
CL2021002842A1 (es) Moléculas inhibidoras de ácido nucleico bicatenario con cadenas de sentido acortadas
BR112021010804A2 (pt) Métodos para expansão seletiva in vivo de populações de células t gama delta e composições das mesmas
CL2025001040A1 (es) Composiciones de iarn de plasminógeno (plg) y métodos de uso de las mismas
MX2021013117A (es) Composiciones y metodos para el tratamiento del cancer.
ES2364166B1 (es) Huella genómica como predictor de respuesta a tratamiento.